Literature DB >> 18288499

Early markers of renal dysfunction in patients with beta-thalassemia major.

Masoumeh Mohkam1, Bibi Shahin Shamsian, Atoosa Gharib, Shahin Nariman, Mohammad T Arzanian.   

Abstract

Studies of renal involvement in thalassemia syndromes have been varied and few. The most important cause of mortality and morbidity in these patients is organ failure due to iron deposition. We report here a cross-sectional study carried out between February 2005 and February 2006 on all beta-thalassemia major patients being treated in Mofid Children's hospital, Tehran. The aim of the study was to detect renal dysfunction in these patients. The patient cohort consisted of 103 patients with various disease severities. Fresh first morning urine samples were collected and analyzed for sodium (Na), potassium (K), calcium (Ca), creatinine (Cr), phosphate, uric acid (UA), N-acetyl beta-D-glucosaminidase (NAG) and amino acids. We also carried out a complete blood count evaluation and assayed fasting blood sugar and serum ferritin, sodium, potassium, creatinine, uric acid and amino acids in all patients. The mean age of our patient cohort was 12.5+/-5.53 years and 53.4% were female. Abnormal levels of urinary NAG were detected in 35.9% of patients (confidence interval 26-45%). Abnormal levels of fractional excretion (FE)-Na, FE-K and FE-UA and abnormal urine protein Pr/Cr and urine Ca/Cr ratios were present in 29.1, 7.8, 52.4, 0.3 and 22.3% of the patients, respectively. There was a significant relationship between urinary NAG and the age of the patient (R=0.35), duration of deferoxamine therapy (R= 0.31), duration of receiving blood transfusions (R=0.34) and level of fasting blood sugar (R=0.2). We concluded that renal disorders are not rare in patients with beta-thalassemia major and that they may increase in terms of frequency with age, increased duration of transfusion and deferoxamine usage and high levels of blood sugar.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288499     DOI: 10.1007/s00467-008-0753-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

1.  Renal function in pediatric patients with beta-thalassemia major.

Authors:  B Aldudak; A Karabay Bayazit; A Noyan; A Ozel; A Anarat; I Sasmaz; Y Kilinç; E Gali; R Anarat; N Dikmen
Journal:  Pediatr Nephrol       Date:  2000-11       Impact factor: 3.714

2.  Effects of deferoxamine on renal function in thalassemia.

Authors:  C B Hyman; H C Gonick; C Agness; R Nadorra; B Landing
Journal:  Birth Defects Orig Artic Ser       Date:  1988

3.  Urinary zinc excretion and zinc status of patients with beta-thalassemia major.

Authors:  Y Aydinok; C Coker; K Kavakli; A Polat; G Nisli; N Cetiner; M Kantar; N Cetingül
Journal:  Biol Trace Elem Res       Date:  1999-11       Impact factor: 3.738

4.  Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.

Authors:  E Voskaridou; E Terpos; S Michail; E Hantzi; A Anagnostopoulos; A Margeli; D Simirloglou; D Loukopoulos; I Papassotiriou
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

5.  Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.

Authors:  P Cianciulli; D Sollecito; F Sorrentino; L Forte; E Gilardi; A Massa; G Papa; S Carta
Journal:  Kidney Int       Date:  1994-08       Impact factor: 10.612

6.  Renal abnormalities in patients with sickle cell-beta thalassemia.

Authors:  K P Katopodis; M S Elisaf; H A Pappas; J C Theodorou; H J Milionis; K L Bourantas; K C Siamopoulos
Journal:  J Nephrol       Date:  1997 May-Jun       Impact factor: 3.902

7.  Renal function in adult beta-thalassemia/Hb E disease.

Authors:  L Ong-ajyooth; P Malasit; S Ong-ajyooth; S Fucharoen; P Pootrakul; S Vasuvattakul; N Siritanaratkul; S Nilwarangkur
Journal:  Nephron       Date:  1998       Impact factor: 2.847

8.  Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.

Authors:  G Koliakos; F Papachristou; A Koussi; V Perifanis; I Tsatra; E Souliou; M Athanasiou
Journal:  Clin Lab Haematol       Date:  2003-04

9.  The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.

Authors:  G Koren; Y Kochavi-Atiya; Y Bentur; N F Olivieri
Journal:  Int J Hematol       Date:  1991-10       Impact factor: 2.490

10.  Renal tubular function in beta-thalassemia.

Authors:  A Sumboonnanonda; P Malasit; V S Tanphaichitr; S Ong-ajyooth; S Sunthornchart; S Pattanakitsakul; S Petrarat; A Assateerawatt; A Vongjirad
Journal:  Pediatr Nephrol       Date:  1998-05       Impact factor: 3.714

View more
  17 in total

1.  GFR in Patients with β-Thalassemia Major.

Authors:  Gai Milo; Revital Feige Gross Nevo; Idit Pazgal; Anat Gafter-Gvili; Ofer Shpilberg; Uzi Gafter; Arie Erman; Pinhas Stark
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-11       Impact factor: 8.237

2.  Renal dysfunction in patients with thalassaemia.

Authors:  Charles T Quinn; Valerie L Johnson; Hae-Young Kim; Felicia Trachtenberg; Maria G Vogiatzi; Janet L Kwiatkowski; Ellis J Neufeld; Ellen Fung; Nancy Oliveri; Melanie Kirby; Patricia J Giardina
Journal:  Br J Haematol       Date:  2011-02-21       Impact factor: 6.998

3.  Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.

Authors:  Enas A Hamed; Nagla T ElMelegy
Journal:  Ital J Pediatr       Date:  2010-05-25       Impact factor: 2.638

4.  Renal function in children with beta-thalassemia major and thalassemia intermedia.

Authors:  Vladislav Smolkin; Raphael Halevy; Carina Levin; Miguel Mines; Waheeb Sakran; Katzap Ilia; Ariel Koren
Journal:  Pediatr Nephrol       Date:  2008-06-25       Impact factor: 3.714

Review 5.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

6.  Early Predictors of Renal Dysfunction in Egyptian Patients with β-Thalassemia Major and Intermedia.

Authors:  Azza A G Tantawy; Nagham El Bablawy; Amira A M Adly; Fatma S E Ebeid
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-09-01       Impact factor: 2.576

7.  Age related secretary pattern of growth hormone, insulin-like growth factor-I & insulin-like growth factor binding protein-3 in postmenopausal women.

Authors:  Akbar Aliasgarzadeh; Morteza Ghojazadeh; Reza Haji-Hoseini; Faezeh Mehanfar; Reza Piri; Mohammad Naghavi-Behzad; Nariman Nezami
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

8.  Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.

Authors:  Caroline Fradette; Vincent Pichette; Éric Sicard; Anne Stilman; Shalini Jayashankar; Yu Chung Tsang; Michael Spino; Fernando Tricta
Journal:  Br J Clin Pharmacol       Date:  2016-07-18       Impact factor: 4.335

9.  Comparing different markers of tubular dysfunction in transfusion-dependent thalassemia patients.

Authors:  Ilham Youssry; Samuel Makar; Khalil Abdelkhalek; Dina Hisham; Happy Sawires
Journal:  Int Urol Nephrol       Date:  2021-06-24       Impact factor: 2.370

10.  Different aspects of kidney function in well-controlled congenital hypothyroidism.

Authors:  Alaleh Gheissari; Mahin Hashemipour; Pooya Khosravi; Atoosa Adibi
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.